摘要
目的探讨抗菌药物莫西沙星联合益生菌培菲康治疗伴有细菌移位的腹泻型肠易激综合征(IBS-D)临床疗效影响。方法选择2017年1月—2018年1月在我院收治的160例IBS-D患者,按照随机数表法将其分为两组,各80例;其中对照组单纯采用抗菌药物莫西沙星进行治疗;观察组在服用莫西沙星4周后,口服培菲康治疗。比较两组患者治疗前后的免疫细胞因子、临床疗效、肝功能指标。结果①两组患者治疗后IL-6、IL-8、TNF、CD^(8+)均降低(t=2.989,P=0.003;t=10.600,P=0;t=11.142,P=0;t=23.583,P=0;t=13.483,P=0;t=47.851,P=0;t=7.583,P=0;t=10.375,P=0);CD^(4+)/CD^(8+)升高(t=14.013,P=0;t=16.663,P=0),且观察组治疗后IL-6、IL-8、TNF、CD^(8+)低于对照组(t=14.583,P=0.00;t=21.934,P=0;t=33.217,P=0;t=12.484,P=0),CD^(4+)/CD^(8+)高于对照组(t=11.465,P=0)。②对照组治疗有效率远低于观察组,差异具有统计学意义(t=112.624,P=0)。③两组患者治疗后腹痛与腹泻症状评分低于治疗前(t=16.435,P=0;t=29.584,P=0;t=18.937,P=0;t=45.764,P=0),且观察组患者评分均明显低于对照组(t=54.586,P=0;t=52.412,P=0)。结论抗菌药物莫西沙星联合益生菌培菲康治疗伴有细菌移位的IBS-D临床疗效显著,能够有效改善细胞炎症因子水平,改善腹痛、腹泻症状情况,值得临床广泛应用。
Objective To investigate the clinical effect of moxifloxacin combined with probiotic bificon in the treatment of diarrhea-predominant irritable bowel syndrome(IBS-D)with bacterial translocation.Methods 160cases of IBS-D patients admitted to our hospital from January 2017 to January 2018 were divided into two groups according to random number table,80 cases in each group.The control group was treated with moxifloxacin alone,while the observation group was treated with pefican orally after taking moxifloxacin for 4 week.Immunocytokines,clinical efficacy and liver function were compared between the two groups before and after treatment.Results(1)After treatment,IL-6,IL-8,TNF and CD^(8+)decreased(t=2.989,P=0.003;t=10.600,P=0;t=11.142,P=0;t=23.583,P=0;t=13.483,P=0;t=47.851,P=0;t=7.583,P=0;t=10.375,P=0),CD^(4+)/CD^(8+)increased(t=14.013,P=0;t=16.663,P=0),and IL-6,IL-8,TNF and CD^(8+)in the observation group were lower than those in the control group(t=14.583,P=0.00;t=21.934,P=0;t=33.217,P=0;t=12.484,P=0),and CD^(4+)/CD^(8+)was higher than those in the control group(t=11.465,P=0).(2)The effective rate of the control group was much lower than that of the observation group,the difference was statistically significant(t=112.624,P=0).(3)The scores of abdominal pain and diarrhea symptoms in the two groups were lower than those before treatment(t=16.435,P=0;t=29.584,P=0;t=18.937,P=0;t=45.764,P=0),and the scores in the observation group were significantly lower than those in the control group(t=54.586,P=0;t=52.412,P=0).Conclusion Antibiotic moxifloxacin combined with probiotics Bifikang has significant clinical efficacy in the treatment of IBS-D with bacterial translocation.It can effectively improve the level of inflammatory cytokines and the symptoms of abdominal pain and diarrhea.It is worthy of wide clinical application.
作者
王勇
王艺霏
康克国
陈孝刚
马骥
Wang Yong;Wang Yi-lin;Kang Ke-guo;Chen Xiao-gang;Ma Ji(Departments Laboratory Department of Sichuan Mianyang 404 Hospital,Mianyang 621000)
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2022年第9期977-980,共4页
Chinese Journal of Antibiotics
关键词
抗菌药物
莫西沙星
益生菌
培菲康
细菌移位
腹泻性肠易激综合征
Antibiotics
Moxifloxacin
Probiotics
Beifeikang
Bacterial translocation
Diarrhea-predominant irritable bowel syndrome
